Market Overview:
The global Ivacaftor API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cystic fibrosis, rising demand for novel therapies, and growing investments by pharmaceutical companies in R&D. Based on type, the Ivacaftor API market can be segmented into min purity less than 98%, min purity 98%-99%, and min purity more than 99%. The min purity less than 98% segment is expected to account for the largest share of the global Ivacaftor API market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period. Based on application, the Ivacaftor API market can be divided into research and pharmaceuticals. The research segment is expected to account for a larger share of the global Ivacaftor API market in 2018. This segment is projected to grow at a CAGR of XX% duringthe forecast period.
Product Definition:
Ivacaftor API is a cystic fibrosis drug which is used to improve lung function and reduce the number of pulmonary exacerbations in patients with cystic fibrosis. It is a potentiator of the CFTR protein, which is responsible for transporting chloride ions across cell membranes. Ivacaftor helps restore normal function to the CFTR protein, improving chloride ion transport and mucus clearance.
Min Purity Less Than 98%:
Min Purity Less Than 98% is the most preferred raw material for manufacturing of drugs. It’s also used as a building block to manufacture other drug molecules. The growing demand for low-purity APIs in pharmaceutical and biopharmaceutical industries is expected to drive market growth over the forecast period.
Min Purity 98%-99%:
Min Purity 98%-99% is a type of crystalline or amorphous form of medicine, which has been used in the formulation of drugs for pulmonary arterial hypertension. Min Purity 98%-99% contains no impurities and has 99.5% purity by weight. It's main application is to formulate the drug for pulmonary arterial hypertension which has been widely accepted across the globe as it provides better pharmacokinetic properties than other formulations including powder and liquid forms.
Application Insights:
The research application dominated the global ivacaftor API market in terms of revenue in 2017. This can be attributed to increasing R&D investments by various companies for the development of new drugs. For instance, Pfizer Inc., one of America's largest pharmaceutical companies has invested around USD 1,200 million for discovering and developing novel medicines that can cure diseases and save lives.
Pharmaceutical is expected to be the fastest-growing application segment over the forecast period owing to growing government initiatives towards improving healthcare infrastructure across countries such as India, China and Australia among others. In addition, there have been significant advancements made in recent years with respect to drug formulations that are suitable for patients suffering from rare diseases or those undergoing kidney dialysis which is further anticipated to boost product demand globally over the forecast period.
Regional Analysis:
North America dominated the global ivacaftor API market in 2017. The presence of key players, advanced healthcare infrastructure and high R&D expenditure are some of the factors responsible for its large share. Furthermore, increasing number of clinical trials and favorable government initiatives to promote new drug development is expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income coupled with growing awareness about new treatment options for CF patients in emerging countries such as China & India. Moreover, increasing investment by governments & private firms in order to improve healthcare facilities is likely boost product demand over the next eight years.
Growth Factors:
- Increasing prevalence of cystic fibrosis (CF)
- Growing demand for novel and effective therapies for CF
- Rising awareness about Ivacaftor API and its benefits among patients and healthcare professionals
- Technological advancements in the field of drug discovery and development
- Availability of government funding for research on rare diseases such as CF
Scope Of The Report
Report Attributes
Report Details
Report Title
Ivacaftor API Market Research Report
By Type
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
By Application
Research, Pharmaceutical
By Companies
Tecoland, FCDA, Jigs chemical, Pharmaffiliates, Struchem, AlchemyPharm, Shijiazhuang Dingmin Pharmaceutical Sciences, Synbest
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
155
Number of Tables & Figures
109
Customization Available
Yes, the report can be customized as per your need.
Global Ivacaftor API Market Report Segments:
The global Ivacaftor API market is segmented on the basis of:
Types
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Pharmaceutical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tecoland
- FCDA
- Jigs chemical
- Pharmaffiliates
- Struchem
- AlchemyPharm
- Shijiazhuang Dingmin Pharmaceutical Sciences
- Synbest
Highlights of The Ivacaftor API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Min Purity Less Than 98%
- Min Purity 98%-99%
- Min Purity More Than 99%
- By Application:
- Research
- Pharmaceutical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ivacaftor API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ivacaftor API is a platform that allows developers to access and manage Ivacaftor data. It provides tools for managing clinical trials, tracking patient progress, and communicating with patients and their caregivers.
Some of the major players in the ivacaftor api market are Tecoland, FCDA, Jigs chemical, Pharmaffiliates, Struchem, AlchemyPharm, Shijiazhuang Dingmin Pharmaceutical Sciences, Synbest.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ivacaftor API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ivacaftor API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ivacaftor API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ivacaftor API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ivacaftor API Market Size & Forecast, 2020-2028
4.5.1 Ivacaftor API Market Size and Y-o-Y Growth
4.5.2 Ivacaftor API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Min Purity Less Than 98%
5.2.2 Min Purity 98%-99%
5.2.3 Min Purity More Than 99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research
6.2.2 Pharmaceutical
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ivacaftor API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ivacaftor API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Min Purity Less Than 98%
9.6.2 Min Purity 98%-99%
9.6.3 Min Purity More Than 99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research
9.10.2 Pharmaceutical
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Min Purity Less Than 98%
10.6.2 Min Purity 98%-99%
10.6.3 Min Purity More Than 99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research
10.10.2 Pharmaceutical
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Min Purity Less Than 98%
11.6.2 Min Purity 98%-99%
11.6.3 Min Purity More Than 99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research
11.10.2 Pharmaceutical
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Min Purity Less Than 98%
12.6.2 Min Purity 98%-99%
12.6.3 Min Purity More Than 99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research
12.10.2 Pharmaceutical
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Min Purity Less Than 98%
13.6.2 Min Purity 98%-99%
13.6.3 Min Purity More Than 99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research
13.10.2 Pharmaceutical
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ivacaftor API Market: Competitive Dashboard
14.2 Global Ivacaftor API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Tecoland
14.3.2 FCDA
14.3.3 Jigs chemical
14.3.4 Pharmaffiliates
14.3.5 Struchem
14.3.6 AlchemyPharm
14.3.7 Shijiazhuang Dingmin Pharmaceutical Sciences
14.3.8 Synbest
